SCHEDULE 13G/A: Muneer A. Satter Discloses 2.6% Passive Stake in Akebia Therapeutics
Beneficial Ownership Disclosure
Muneer A. Satter has filed an amended Schedule 13G, reporting a 2.6% passive beneficial ownership stake in Akebia Therapeutics, Inc. as of December 31, 2024.
Summary
- Muneer A. Satter beneficially owns 5,747,906 shares of Akebia Therapeutics, Inc. common stock.
- This ownership represents 2.6% of the company's outstanding common stock.
- The shares are held through various entities, including 4,097,657 shares by Alerce Medical Technology Partners, L.P., 939,947 shares by Satter Medical Technology Partners, L.P., 278,558 shares by Muneer A. Satter Revocable Trust, and 431,744 shares by other trusts and entities.
- Mr. Satter maintains sole voting and dispositive power over all reported shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Akebia Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing (Schedule 13G) disclosing beneficial ownership, which is generally neutral in sentiment as it does not contain operational or financial performance updates, but rather a passive investment disclosure.
Positives
- Muneer A. Satter, a recognized investor, maintains a beneficial ownership stake in Akebia Therapeutics, Inc., indicating continued interest in the company.
Negatives
- The document does not contain explicit negative information regarding the company's operations or financial performance.
Risks
- NA
Future Outlook
NA
Industry Context
NA
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant investor's stake in the company.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (beneficial ownership calculation date) |
| 02/07/2025 | Date of filing of this Schedule 13G Amendment No. 3 |
Keywords
Akebia Therapeutics, Muneer A. Satter, Schedule 13G, beneficial ownership, common stock, passive investment, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.